ADAG Stock Analysis: Buy, Sell, or Hold?
ADAG - Adagene Inc. American Depositary Shares
$4.02
-0.07 (-1.71%)
âŧ
5d:
+8.65%
30d:
+19.29%
90d:
+6.07%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Apr 01, 2026
0d
Get Alerted When ADAG Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ADAG is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ADAG is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: ADAG is currently trading at $4.02, which is considered slightly high relative to its 30-day fair value range of $3.52 to $3.96.
Technical Outlook: Technically, ADAG is showing sideways momentum. Immediate support is located at $3.58, while resistance sits at $4.24.
Market Sentiment: ADAG scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.74 (+167.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ADAG is showing sideways momentum. Immediate support is located at $3.58, while resistance sits at $4.24.
Market Sentiment: ADAG scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.74 (+167.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$3.52 -
$3.96
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
42.1%
All Signals
- BEARISH: Weak technical setup (35/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 167.2% below Wall St target ($10.74)
- WARNING: Composite score 42/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.52 -
$3.96
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$3.58
Resistance Level
$4.24
Current Trend
Sideways
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.18
Wall Street Target
$10.74
(+167.2%)
Revenue Growth (YoY)
7332.8%
Profit Margin
-220.8%
Share & Embed Analysis
Last updated: August 24, 2026 7:36 AM ET
Data refreshes hourly during market hours. Next update: 8:36 AM
Data refreshes hourly during market hours. Next update: 8:36 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ADAG showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
29 analysts |
$91 | 42 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 66 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 52 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 41 HOLD |
